BD (BDX) Q1 2026 earnings review
Transition Quarter: Pivot to 'New BD' Masks Earnings Drop
BD kicked off FY26 with a massive strategic shift—the divestiture of its Life Sciences & Diagnostics business to Waters Corp is closing. The rationale is clear in the numbers: while the legacy Life Sciences unit dragged revenue down 8.3%, the core 'New BD' portfolio grew 2.5% FXN. However, the transition is painful. Adjusted EPS fell 15% to $2.91, and margins compressed. Management's FY26 guidance for 'New BD' projects stability rather than speed, with low-single-digit growth.
🐂 Bull Case
The sale of the Life Sciences unit removes a significant drag. The divested unit revenue shrank 8.3% this quarter, while the remaining 'New BD' segments (Medical, Interventional, Connected Care) all posted growth.
The Interventional segment continues to outperform, growing 5.8% reported (5.1% FXN), driven by double-digit growth in Urology and Critical Care. This high-margin segment is now a larger piece of the pie.
🐻 Bear Case
Adjusted EPS collapsed 15% YoY to $2.91. While tax timing and divestiture noise play a role, the drop in profitability during this transition period is steep and raises questions about immediate earnings power.
The debut guidance for 'New BD' calls for 'low single-digit' revenue growth in FY26. For a company pitching a purified, higher-growth profile post-divestiture, this initial target is underwhelming.
⚖️ Verdict: ⚪
Neutral. The strategic logic of dumping the shrinking Life Sciences business is sound, but the immediate financial cost is a 15% drop in EPS and messy financials. Investors need to see if 'New BD' can actually accelerate beyond low-single digits.
Key Themes
Life Sciences Meltdown
The Life Sciences segment, which is being sold to Waters Corp, deteriorated significantly just before the exit. Revenue fell 8.3% reported (-10.5% FXN), with Biosciences down nearly 12% FXN. This sharp decline dragged total company performance down to just +1.6% reported, validating the sale but creating a weak headline print.
Connected Care & Interventional Strength
The core of 'New BD' is performing. Connected Care grew 5.5% (4.7% FXN) and Interventional grew 5.8% (5.1% FXN). Strength was broad-based: Medication Management (Infusion) and Urology (PureWick) remain key growth engines that are shielding the company from the Life Sciences weakness.
Tariffs & Macro Headwinds
Management flagged risks related to new US government tariffs and global supply chain disruptions. While they did not quantify a specific Q1 impact, the risk factor language specifically cites 'imposition of new and existing tariffs' as a variable for FY26 guidance.
Profitability Squeeze
Adjusted Diluted EPS fell 15.2% to $2.91. While GAAP EPS rose due to comparison noise, the core operational profitability took a hit. Management cited tax matters and separation costs, but the magnitude of the drop suggests negative operating leverage as revenue growth (0.4% FXN) failed to cover cost inflation.
BioPharma Resilience
BioPharma Systems (formerly Pharmaceutical Systems) grew 2.7% (1.0% FXN). While modest, this segment is critical for the 'New BD' story as it pivots to high-growth biologics and GLP-1 delivery. The $110M investment in Nebraska for glass prefillable syringes confirms this remains a high-priority capital destination.
Other KPIs
Decelerating. Growth slowed to 1.6% reported (0.4% FXN), down from the ~7-8% levels seen in late FY25. This deceleration is almost entirely driven by the collapsing Life Sciences business.
Reversing. A sharp contraction of 15.2% from $3.43 in the prior year period. This is a significant deviation from the growth trend seen in FY25 (FY25 full year EPS grew ~9%).
Stable. Slightly down from $693 million in the prior year period (-5%). Despite the earnings volatility, cash generation remains relatively consistent.
Guidance
Stable. This implies a continuation of the current 'New BD' trend (2.5% FXN in Q1) rather than an acceleration. It suggests a conservative outlook for the core business post-separation.
Rebasing. This number is lower than the prior consolidated FY25 result of $14.40, reflecting the loss of Life Sciences income. The focus is now on the growth rate off this new base.
Stable. The 'plus' likely reflects a minor tailwind from foreign currency translation compared to the FXN guide.
Key Questions
Margins Post-Separation
Adjusted EPS fell 15% this quarter. What is the baseline operating margin for 'New BD' starting Q2, and are dis-synergies from the separation fully ring-fenced?
Accelerating New BD
Guidance calls for 'low single-digit' growth. With high-growth areas like GLP-1 delivery and PureWick, why is the aggregate growth ambition for the purified company so modest?
Tariff Exposure Quantified
You mention tariff risks in the release. What is the specific dollar impact embedded in the $12.35-$12.65 EPS guidance for FY26?